Skip to main content
. 2019 Dec 6;15(12):e1008140. doi: 10.1371/journal.ppat.1008140

Fig 3. Recombinant-IL-22 treatment prolongs the survival of Mtb-infected T2DM mice.

Fig 3

One month after the induction of diabetes, T2DM mice were infected with ~100 CFU of aerosolized Mtb. Five months after Mtb infection, the mice were treated intravenously with recombinant IL-22 (100 ng/kg body weight, twice weekly) or PBS. (A) A schematic representation of Mtb infection and recombinant IL-22 treatment in T2DM mice is shown. (B) Survival of Mtb-infected T2DM mice treated with recombinant IL-22 or PBS. Survival curves were compared using the log rank test. Data were pooled from two independent experiments (n = 5 mice per group per experiment). (C) Bacterial burden in lungs at 1 month post recombinant IL-22 or PBS treatment. (D) Serum insulin levels were measured by ELISA at 1 month after recombinant IL-22 treatment. (E to G) free fatty acid, triglyceride and Serum cholesterol, levels were measured by biochemical-based assays at 1 month after recombinant IL-22 treatment. (H) Random blood glucose sampling at twenty-day intervals for up to 8 months. Five mice per group were used. The mean values, SDs and p-values are shown.